doi:10.16150/j.1671-2870.2020.02.003

Abstract

CLC Number:

R733.3

References 24

[1]	Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405. doi: 10.1182/blood-2016-03-643544 URL
[2]	Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloprolife-rative disorders[J]. Lancet, 2005, 365(9464):1054-1061. doi: 10.1016/S0140-6736(05)71142-9 URL
[3]	Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia[J]. PLoS Med, 2006, 3(7):e270. doi: 10.1371/journal.pmed.0030270 pmid: 16834459
[4]	Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmuta-ted JAK2[J]. N Engl J Med, 2013, 369(25):2391-2405. doi: 10.1056/NEJMoa1312542 URL
[5]	Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis[J]. N Engl J Med, 2007, 356(5):459-468. doi: 10.1056/NEJMoa065202 URL
[6]	Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis[J]. Blood, 2014, 123(22):e123-e133. doi: 10.1182/blood-2014-02-554634 URL
[7]	Shuai K, Ziemiecki A, Wilks AF, et al. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins[J]. Nature,1993 Dec 9; 366(6455):580-583. doi: 10.1038/366580a0 URL
[8]	O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses[J]. Immunity, 2008, 28(4):477-487. doi: 10.1016/j.immuni.2008.03.002 pmid: 18400190
[9]	Nishanth G, Wolleschak D, Fahldieck C, et al. Gain of function in Jak2V617F-positive T-cells[J]. Leukemia, 2017, 31(4):1000-1003. doi: 10.1038/leu.2017.6 pmid: 28074070
[10]	Prestipino A, Emhardt AJ, Aumann K, et al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms[J]. Sci Transl Med, 2018, 10(429),pii:eaam7729.
[11]	Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?[J]. Blood, 2012, 119(14):3219-3225. doi: 10.1182/blood-2011-11-394775 pmid: 22318201
[12]	Fleischman AG, Aichberger KJ, Luty SB, et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms[J]. Blood, 2011, 118(24):6392-6398. doi: 10.1182/blood-2011-04-348144 pmid: 21860020
[13]	Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis[J]. Blood, 2006, 108(9):3223-3224. doi: 10.1182/blood-2006-05-021527 pmid: 17057021
[14]	Hobbs CM, Manning H, Bennett C, et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia[J]. Blood, 2013, 122(23):3787-3797.
[15]	Leroy E, Constantinescu SN. Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition[J]. Leukemia, 2017, 31(5):1023-1038. doi: 10.1038/leu.2017.43 pmid: 28119526
[16]	Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J]. N Engl J Med, 2012, 366(9):799-807. doi: 10.1056/NEJMoa1110557 URL
[17]	Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis[J]. N Engl J Med, 2012, 366(9):787-798. doi: 10.1056/NEJMoa1110556 URL
[18]	Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera[J]. N Engl J Med, 2015, 372(5):426-435. doi: 10.1056/NEJMoa1409002 URL
[19]	Passamonti F, Saydam G, Lim L, et al. RESPONSE 2: a phase 3b study evaluating the efficacy and safety of ruxo-litinib in patients with hydroxyurea - resistant/intolerant polycytheinia vera versus best available therapy[J]. J Clin Oncol, 2014, 32:15.
[20]	Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide[J]. Blood, 2017, 130(17):1889-1897. doi: 10.1182/blood-2017-05-785790 pmid: 29074595
[21]	Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib(SIMPLIFY 2): a randomised, open-label, phase 3 trial[J]. Lancet Haematol, 2018, 5(2):e73-e81.
[22]	Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial[J]. Lancet Haematol, 2017, 4(5):e225-e236.
[23]	Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial[J]. JAMA Oncol, 2015, 1(5):643-651. doi: 10.1001/jamaoncol.2015.1590 pmid: 26181658
[24]	Verstovsek S, Talpaz M, Ritchie E, et al. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis[J]. Leukemia, 2017, 31(2):393-402. doi: 10.1038/leu.2016.215 pmid: 27479177

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 24

Related Articles 9

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(04): 434-437.
[2]	CHANG Rui, YANG Yanzhao, KONG Deyan, XU Jiaxu, CAO Qiqi, YANG Wenjie, YAN Fuhua, DONG Haipeng. Application of different tube voltage-current protocol in combination with KARL iterative reconstruction in CT chest scanning for novel coronavirus pneumonia screening [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 182-187.
[3]	YE Chenglin, YAO Yonghua, CHEN Zhen, JIA Lin. Application of plastic-embedded bone marrow biopsy in diagnosing myelodysplastic syndrome with thrombocytopenia [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 177-181.
[4]	XIAO Chao, TAO Ying, SONG Luxi, ZHAO Youshan, WU Lingyun, CHANG Chunkang. Clinical analysis of 88 patients with myeloproliferative neoplasm [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 115-121.
[5]	. [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 104-110.
[6]	LU Hongyu, CAO Yafeng, GU Jun, WANG Jing, CHEN Mei, SONG Luxi. Diagnostic value of nerve electrophysiological studies for Bortezomib-induced peripheral neuropathy in multiple myeloma patients [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 640-644.
[7]	. [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 623-629.
[8]	SONG Dandan, CHANG Chunkang, GUO Juan, XU Feng, ZHAO Youshan, WU Lingyun. The abnormal percentage of bone marrow macrophages and its clinical significances in myelodysplastic syndromes [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(04): 439-443.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(01): 123-126.